XBIO - Xenetic Biosciences, Inc. Latest News | Finranks

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting Continued royalty generation provides recurring, non-dilutive funding to support continued investment in core development programs FRAMINGHAM, MA / ACCESS Newswire / August 7, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update on continued execution of its long-term strategy to advance its proprietary DNase platform through scientific collaboration and translational research. Recent Highlights Positive preclinical and translational data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhanced CAR T-cell expansion, persistence, tumor control and survival across preclinical hematologic cancer models Announced that collaboration partner, PeriNess Ltd.

Videos

No Data

There is no data to display

Press releases

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting Continued royalty generation provides recurring, non-dilutive funding to support continued investment in core development programs FRAMINGHAM, MA / ACCESS Newswire / August 7, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update on continued execution of its long-term strategy to advance its proprietary DNase platform through scientific collaboration and translational research. Recent Highlights Positive preclinical and translational data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhanced CAR T-cell expansion, persistence, tumor control and survival across preclinical hematologic cancer models Announced that collaboration partner, PeriNess Ltd.